Revolutionizing Respiratory Health: 4DMedical (ASX:4DX) Achieves New Milestones

April 10, 2025 12:43 PM AEST | By Team Kalkine Media

Google News:

Revolutionizing Respiratory Health: 4DMedical (ASX:4DX) Achieves New Milestones — Image source: shutterstock

Recent News

BE OPEN Art: the winners of the Oceania regional competition revealed

Small Businesses Embrace Social-- But Could be Missing a Trick in the...

DXC Technology Appoints Professional Services Industry Veteran Ramnath...

The Power She Brings: Entergy Texas Celebrates International Women in...

Highlights

4DMedical (4DX) secures contracts enhancing stem cell therapy and lung implant trials.

Recognized in U.S. Congressional testimony for advancing veteran care.

CEO Andreas Fouras emphasizes the impact of their technology on treatment innovations.

4DMedical (ASX:4DX), a pioneering medical technology company, has recently marked significant achievements by securing new contracts and receiving commendation during a U.S. Congressional hearing. These developments underscore the company’s influential role in pushing the boundaries of respiratory health diagnostics and treatment.

Industry Partnerships Expand The company has successfully entered into two new contracts, broadening its scope in the medical field. The first agreement involves collaboration with SMS Biotech to support a Phase 1 clinical trial aimed at treating Chronic Obstructive Pulmonary Disease (COPD) using stem cell therapies. This contract will see 4DMedical providing 42 quantitative assessments, essential for the trial at Cabrini Health, with a contract value of US$40,000.

The second partnership is with a renowned multinational lung device developer. This collaboration focuses on supporting clinical trials for an innovative lung implantable device. These partnerships not only demonstrate the versatility of 4DMedical’s advanced imaging technology but also its growing acceptance as a crucial tool in respiratory healthcare advancements.

Congressional Recognition In a notable acknowledgment of its impact, 4DMedical's technology was highlighted during Congressional testimony on the modernization of VA Healthcare. Jeff DiLullo, Executive Vice President and CEO of Philips North America, commended 4DMedical’s FDA-cleared cardiopulmonary software. This technology transforms standard CT scans into detailed four-dimensional images, significantly enhancing pulmonary function assessments for veterans. Such recognition at a national level emphasizes the significance and reliability of 4DMedical’s contributions to healthcare.

Forward-Looking Statements from Leadership Andreas Fouras, the Founder and CEO of 4DMedical, expressed enthusiasm about the new partnerships. He noted that these collaborations are a testament to the growing demand for their proprietary imaging technology. According to Fouras, the company’s tools are instrumental in providing detailed structural imaging and functional insights, thereby accelerating the development and success of innovative treatments. His comments reflect a clear vision for the company’s future in contributing effectively to modern medical solutions.

4DMedical (4DX) continues to make substantial strides in enhancing respiratory health diagnostics and treatment, supported by strategic partnerships and significant recognition. These efforts are not only transforming medical practices but are also setting new standards in healthcare innovation, benefiting a broad range of stakeholders, including those in veteran care.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.